Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261585 | 0.91 | MMP8 (0.84) | MMP8MMP13HDAC1HDAC4HDAC6 | |
| SCHEMBL5598935 | 0.87 | MMP8 (0.77) | MMP8HDAC1HDAC4HDAC6MMP9 | |
| SCHEMBL5598938 | 0.87 | MMP8 (0.77) | MMP8HDAC1HDAC4HDAC6MMP9 | |
| SCHEMBL10061363 | 0.85 | MMP8 (0.74) | MMP8MMP13HDAC1HDAC4HDAC6 | |
| SCHEMBL10077678 | 0.83 | MMP8 (0.71) | MMP8MMP13HDAC1MMP9HDAC3 | |
| SCHEMBL16558599 | 0.82 | MMP8 (0.69) | MMP8MMP13HDAC1HDAC4HDAC6 | |
| SCHEMBL24687567 | 0.81 | HSD17B3 (0.69) | MMP8HDAC1HDAC4HDAC6MMP9 | |
| SCHEMBL3222733 | 0.81 | MAOB (0.73) | MMP8HDAC1HDAC4HDAC6MMP9 | |
| SCHEMBL3222739 | 0.81 | MAOB (0.73) | MMP8HDAC1HDAC4HDAC6MMP9 | |
| SCHEMBL10061352 | 0.81 | MMP8 (0.67) | MMP8MMP13HDAC1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675576-B2 | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170158605-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2017-06-08 | — | — | US | disclosed |
| US-9556105-B2 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160031795-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2016-02-04 | — | — | US | disclosed |
| US-9220695-B2 | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-12-29 | — | — | US | disclosed |
| US-9187406-B2 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | CHEM-MASTER INTERNATIONAL, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120095051-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | CHEM-MASTER INTERNATIONAL, INC. | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | MMP8 3046/4885MMP13 886/4885HDAC1 82/4885 |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | ANTXR2, APAF1, LITAF | MMP8 248/4885MMP13 928/4885HDAC1 406/4885 |
| US-20120095051-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | NFKBIA, NFKB1, NFKB2 | MMP8 18/4885MMP13 11/4885HDAC1 134/4885 |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | MMP8 3046/4885MMP13 886/4885HDAC1 82/4885 |
| US-20170158605-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | NFKBIA, NFKB1, NFKB2 | MMP8 18/4885MMP13 11/4885HDAC1 134/4885 |
| US-20160031795-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES | NFKBIA, NFKB1, NFKB2 | MMP8 18/4885MMP13 11/4885HDAC1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.